secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunoGen, Inc. (—)
CIK:        0000855654
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001104659-23-072241
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunoGen annual meeting: directors elected, say-on-pay approved, bylaws amended
--------------------------------------------------------------------------------

- Shareholders fixed board size at nine: 156,535,922 for, 435,617 against, 678,206 abstain.
- Nine directors elected; highest vote for Mark J. Enyedy (155,483,440 for), lowest for Dean J. Mitchell (108,169,736 for, 49,480,009 withheld).
- Advisory say-on-pay approved: 151,434,309 for (96.1% of votes cast); frequency vote selects one year with 155,975,455 votes (99.5% of votes cast).
- Ratification of Ernst & Young LLP as auditor: 177,531,372 for, 4,513,445 against, 774,118 abstain.
- Bylaws amended effective June 14, 2023 to incorporate universal proxy rules (Rule 14a-19) and enhance shareholder nomination/disclosure procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/855654/000110465923072241/0001104659-23-072241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/855654/000110465923072241/tm2318847d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-072241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer